1-5 of 5
Shih-Ting Tsao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Free
Lung-Ji Chang, PhD, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Xun Lai, MD, Rui Huang, MD& PhD, Shih-Ting Tsao, MSc, Yu-Chen Liu, MSc, Rui Zhang, MSc, Lan Deng, MDPhD, Xuan Zhou, MD, Hongyu Zhang, PhD MD, Wenli Zhang, MD, Yuchen Li, MSc
Journal: Blood
Blood (2018) 132 (Supplement 1): 225.
https://doi.org/10.1182/blood-2018-99-114396
Published: 2018
Journal Articles

Double CD19/CD22 Chimeric Antigen Receptor-Modified T Cells for the Treatment of Stage IV Relapsed and Refractory Follicular Lymphoma

Free
Xun Lai, MD, Xuezhong Gu, MD, Shih-Ting Tsao, MSc, Qin Zhang, PhD, Yu-Chen Liu, MSc, Jiang Yaxian, PhD, Li Yan, MD, Jun Chun, MD, Rui Zhang, MSc, Yunyun Du, MD, Xiaoli Gao, MD, Yingyu Yang, Xiaolian Qiu, Mingjing Fang, MA, Song Wei, PhD, Lung-Ji Chang, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5154.
https://doi.org/10.1182/blood.V130.Suppl_1.5154.5154
Published: 2017
Journal Articles

Durable Remission after Salvage Chemotherapy with Combining Bortezomib and Vorinostat Followed By CD19 CAR-T Therapy in a Patient with MLL-Rearranged ALL after Early Relapse Post Allogeneic Hematopoietic Stem Cell Transplantation

Free
Nobuhiro Nishio, MD PhD, Kai Wang, MDPhD, Kotaro Narita, MD, Shinsuke Kataoka, MD, Hironobu Kitazawa, MD, Motoharu Hamada, MD, Daisuke Ichikawa, MD, Rieko Taniguchi, MD, Norihiro Murakami, MD, Daiei Kojima, MD, Kyogo Suzuki, MD, Nozomu Kawashima, MD PhD, Eri Nishikawa, MD PhD, Yusuke Okuno, MD PhD, Atsushi Narita, MD PhD, Hideki Muramatsu, MD PhD, Asahito Hama, Shih-Ting Tsao, MSc, Maoquan Qin, MDPhD, Huyong Zheng, MD PhD, Lung-Ji Chang, PhD, Seiji Kojima, MD PhD, Yoshiyuki Takahashi, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3334.
https://doi.org/10.1182/blood.V130.Suppl_1.3334.3334
Published: 2017
Journal Articles

Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China

Free
Lihua Yang, MDPhD, Xiaoli Ma, MDPhD, Yu-Chen Liu, MSc, Wen Zhao, MDPhD, Lihua Yu, PhD, Maoquan Qin, MDPhD, Guanghua Zhu, MDPhD, Kai Wang, MDPhD, Xiaodong Shi, MD, Zhaoxia Zhang, MD, Jingfu Wang, MD, Yuan Sun, MD, Lujia Dong, MD, Shih-Ting Tsao, MSc, Rui Zhang, MSc, Lung-Ji Chang, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3335.
https://doi.org/10.1182/blood.V130.Suppl_1.3335.3335
Published: 2017
Journal Articles

Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study

Free
Lung-Ji Chang, PhD, Lujia Dong, MD, Yu-Chen Liu, MSc, Shih-Ting Tsao, MSc, Ya-Chen Li, PhD, Li Liu, MD, Zhiyong Gao, MD, Xiyou Tan, MD, Dao-Pei Lu, MD, Jian-Ping Zhang, Jing-Bo Wang, Yu-Ming Ying, MD, Le-Ping Zhang, MD, Huyong Zheng, MD PhD, Kai Wang, MD PhD, Xiao-Li Zheng, MD, Heng-Xiang Wang, MD, Xun Lai, MD, Dong Li, MD
Journal: Blood
Blood (2016) 128 (22): 587.
https://doi.org/10.1182/blood.V128.22.587.587
Published: 2016